2016
DOI: 10.1007/s10198-016-0815-0
|View full text |Cite
|
Sign up to set email alerts
|

Cost analysis of whole genome sequencing in German clinical practice

Abstract: The estimated costs of WGS currently exceed the prediction of a 'US$1000 per genome', by more than a factor of 3.8. In particular, the material costs in themselves exceed this predicted cost.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
41
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 29 publications
(42 citation statements)
references
References 36 publications
(37 reference statements)
0
41
0
1
Order By: Relevance
“…The report by the Foundation for Genomics and Population Health 25 described the costs of WES for colorectal cancer in three UK National Health Service laboratories. Plöthner et al 26 investigated the costs associated with executing WGS in German clinical practice. Sabatini et al 27 conducted a bottom-up cost study of WES in Canada and compared the findings with the costs of the traditional clinical pathway for diagnosing neurodevelopmental disorders, using payer cost-impact models.…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…The report by the Foundation for Genomics and Population Health 25 described the costs of WES for colorectal cancer in three UK National Health Service laboratories. Plöthner et al 26 investigated the costs associated with executing WGS in German clinical practice. Sabatini et al 27 conducted a bottom-up cost study of WES in Canada and compared the findings with the costs of the traditional clinical pathway for diagnosing neurodevelopmental disorders, using payer cost-impact models.…”
Section: Resultsmentioning
confidence: 99%
“…3,[31][32][33][34][35][36][37][38][39][40][41][42] Seven studies presented data on the costs of WES or WGS testing pathways, [24][25][26][27][43][44][45] and eight studies presented data on clinically relevant outcome measures for these tests. 5,6,[8][9][10][46][47][48] Of the eight full economic evaluations, two were CUAs 22,23 and six were CEAs, published between 2014 and 2017 in Australia (2), the United States (1), the UK (1), the Netherlands (1), and Canada (1).…”
Section: Study Characteristicsmentioning
confidence: 99%
See 3 more Smart Citations